HC Wainwright Predicts Reduced Earnings for Legend Biotech

Legend Biotech logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its Q3 2027 EPS estimate for Legend Biotech to $0.32 from $0.44, while maintaining a Buy rating. It forecasts Q4 2027 EPS of $0.48.
  • Legend Biotech reported quarterly EPS of $0.14, beating the $0.01 consensus estimate, while revenue of $359.5 million came in slightly below forecasts and rose 32% year over year.
  • Analyst views are mixed but lean positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $48.64, based on nine Buy, six Hold, and one Sell rating.
  • Five stocks we like better than Legend Biotech.

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) - Research analysts at HC Wainwright dropped their Q3 2027 EPS estimates for shares of Legend Biotech in a research report issued on Wednesday, November 11th. HC Wainwright analyst M. Kapoor now expects that the company will earn $0.32 per share for the quarter, down from their previous forecast of $0.44. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Legend Biotech's Q4 2027 earnings at $0.48 EPS.

A number of other research firms have also weighed in on LEGN. Evercore lowered Legend Biotech from an "outperform" rating to an "in-line" rating and set a $20.00 target price for the company. in a report on Friday, November 13th. Raymond James Financial reiterated an "outperform" rating and issued a $58.00 price target on shares of Legend Biotech in a report on Monday, July 27th. TD Cowen reduced their price target on Legend Biotech from $29.00 to $24.00 and set a "hold" rating for the company in a research report on Wednesday, August 12th. Weiss Ratings upgraded Legend Biotech from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, November 9th. Finally, JPMorgan Chase & Co. dropped their price objective on Legend Biotech from $35.00 to $33.00 and set a "neutral" rating on the stock in a research report on Friday, October 9th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $48.64.

Check Out Our Latest Report on Legend Biotech

Legend Biotech Stock Performance

NASDAQ LEGN opened at $16.25 on Thursday. The company has a market cap of $3.15 billion, a PE ratio of -1,623.38 and a beta of 0.55. The firm's 50 day moving average price is $19.30 and its 200-day moving average price is $22.10. Legend Biotech has a 52-week low of $15.75 and a 52-week high of $37.50.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.01 by $0.13. Legend Biotech had a negative net margin of 0.02% and a negative return on equity of 0.03%. The business had revenue of $359.50 million during the quarter, compared to analyst estimates of $361.46 million. During the same quarter in the previous year, the business posted ($0.05) EPS. The company's quarterly revenue was up 32.0% compared to the same quarter last year.

Institutional Investors Weigh In On Legend Biotech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aquatic Capital Management LLC acquired a new stake in Legend Biotech in the third quarter worth about $1,399,000. Lighthouse Investment Partners LLC acquired a new position in shares of Legend Biotech during the third quarter valued at about $770,000. Ieq Capital LLC acquired a new position in shares of Legend Biotech during the third quarter valued at about $937,000. Public Sector Pension Investment Board raised its position in shares of Legend Biotech by 3.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 26,789 shares of the company's stock valued at $533,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of Legend Biotech by 484.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 68,698 shares of the company's stock valued at $1,294,000 after purchasing an additional 56,936 shares during the last quarter. 70.89% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Carlos Santos sold 5,430 shares of the company's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $9.14, for a total transaction of $49,630.20. Following the transaction, the chief financial officer directly owned 14,246 shares of the company's stock, valued at approximately $130,208.44. This represents a 27.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $9.46, for a total value of $258,920.20. Following the sale, the director owned 52,731 shares of the company's stock, valued at approximately $498,835.26. This represents a 34.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.02% of the company's stock.

Legend Biotech Company Profile

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson's Innovative Medicine business, which collaborates on its commercialization.

Recommended Stories

Earnings History and Estimates for Legend Biotech (NASDAQ:LEGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Legend Biotech Right Now?

Before you consider Legend Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.

While Legend Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines